The U.S. Food and Drug Administration has opened a critical public comment period on menopause hormone therapy following an expert panel discussion held on July 17, 2025, that examined the complex risks and benefits of hormone replacement treatments for women experiencing menopause.
The FDA Expert Panel on Menopause and Hormone Replacement Therapy for Women focused specifically on evaluating the risks of breast cancer, uterine cancer, and cardiovascular complications versus the potential benefits for bone health, genitourinary systems, cardiovascular health, and cognitive function. The panel’s discussions centered on data regarding how risks and benefits may differ based on the age when hormone therapy begins, the specific formulation used, and dosage levels since the original Women’s Health Initiative (WHI) Study was published.
Public Input Shapes Future Treatment Guidelines
Following the expert panel meeting, the FDA opened a public docket to collect broad comments from healthcare professionals, patients, and researchers regarding menopause hormone therapy. The agency is particularly interested in receiving perspectives on how hormone therapy affects breast cancer risk, cardiovascular disease, genitourinary systems, bone health, and dementia. The comment period officially closed on September 24, 2025, at 11:59 PM Eastern Time.
The FDA’s request for public input represents part of a broader effort to understand various perspectives on safety considerations and the clinical use of hormone therapy for menopause-related conditions. The agency has specifically asked for data that could support potential updates to product labeling for hormone therapy medications.
Healthcare experts note that this regulatory review comes at a crucial time, as millions of American women navigate menopause each year. The timing, duration of use, type of estrogen and progestogen utilized, and delivery methods including route of administration all factor into the risk-benefit calculation for individual patients.
Growing Focus on Women’s Health Research
This FDA initiative aligns with a broader movement toward increased investment and focus on women’s health research. Recent data shows that women spend an average of nine years of their lives in poor health, which is 25 percent more compared to men, yet research funding for women-specific health conditions remains inadequate.
The FDA’s examination of menopause hormone therapy reflects growing recognition that women’s health has been systematically underserved by healthcare systems. Organizations like the Society for Women’s Health Research have been advocating for increased federal funding and focus on women’s health research, with support spanning both sides of the political aisle.
The expert panel’s work builds upon decades of research since the Women’s Health Initiative Study, which significantly impacted how clinicians and patients approach hormone replacement therapy. New data and analytical methods have provided additional insights into when and how hormone therapy might be safely and effectively used for managing menopause symptoms.
While the FDA will not reply individually to comment submissions, the agency has committed to considering all feedback received by the September 24 deadline as it evaluates potential regulatory changes. The results of this review process could significantly impact treatment options and safety information available to the millions of American women who experience menopause each year.